Viking Therapeutics, Inc. (VKTX) Q1 2017 Earnings Results

Viking Therapeutics Misses on EPS, Stock Down 0.72%

Viking Therapeutics reported a loss of $0.23 per share for Q1 2017, with no revenue figures disclosed. The stock reacted negatively, dropping 0.72%. The lack of guidance and specific revenue details may have contributed to investor uncertainty.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.23	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Neutral

Management acknowledged the challenges faced during the quarter. They emphasized their commitment to advancing their clinical programs.

Management did not provide specific updates on revenue or guidance.

The focus remains on ongoing clinical trials and product development.

Viking Therapeutics Misses on EPS, Stock Down 0.72%

Key numbers

Management commentary

Viking Therapeutics, Inc.

More earnings this week

Viking Therapeutics Misses on EPS, Stock Down 0.72%

Key numbers

Management commentary